Kindeva Executive and Leadership Team

David Stevens, the Chief Executive Officer at Kindeva, directs the overarching strategic vision for the global contract development and manufacturing organization. Stevens architects long-term growth initiatives by aligning complex drug delivery technologies with evolving pharmaceutical market demands. Overseeing the integration of inhalation, transdermal, and connected drug delivery platforms, the Chief Executive Officer ensures operational excellence across all international facilities. This leadership role involves constant collaboration with the Board to maintain high standards in product development and commercial manufacturing. By prioritizing innovation in microstructured transdermal systems, David Stevens drives the company toward sustained competitive advantage. The Chief Executive Officer fosters a culture of precision and reliability, ensuring that every client program meets stringent regulatory requirements. Through decisive management of global resources, Stevens secures the company position as a premier partner for pharmaceutical companies seeking advanced, scalable drug delivery solutions.

Daniel Speciale, the Chief Financial Officer at Kindeva, manages the fiscal health and capital allocation strategies for the organization. Speciale oversees financial planning, reporting, and risk management to support the expansion of complex drug delivery programs. By optimizing cost structures across manufacturing sites, the Chief Financial Officer ensures the company maintains profitability while investing in cutting-edge pharmaceutical technologies. This role requires close coordination with executive leadership to evaluate investment opportunities in inhalation and transdermal delivery systems. Daniel Speciale directs the financial infrastructure necessary to sustain global operations and meet the needs of diverse pharmaceutical customers. Through rigorous analysis of market trends and operational performance, the Chief Financial Officer provides the data-driven insights required for strategic decision-making. Speciale maintains fiscal discipline, ensuring that the company remains well-positioned to fund future research and development initiatives while delivering consistent value to stakeholders.

Brian Schubmehl, the Chief Human Resources Officer at Kindeva, directs the talent acquisition, organizational development, and employee engagement strategies. Schubmehl architects programs that attract and retain specialized experts in pharmaceutical formulation and complex drug delivery manufacturing. Overseeing the workforce across global operations, the Chief Human Resources Officer ensures that the company culture aligns with the mission of delivering high-quality medical solutions. This leadership role involves designing performance management systems that incentivize innovation and operational efficiency. Brian Schubmehl drives initiatives to foster a diverse and inclusive environment, which remains critical for solving complex technical challenges in the pharmaceutical industry. By aligning human capital with the strategic goals of the organization, the Chief Human Resources Officer supports the scaling of manufacturing capabilities. Schubmehl maintains a focus on professional development, ensuring that the workforce possesses the necessary skills to advance the company portfolio of inhalation and transdermal technologies.

Mike Cowhig, the Chief Legal Officer at Kindeva, manages all legal affairs, regulatory compliance, and intellectual property strategies for the organization. Cowhig oversees the protection of proprietary technologies related to inhalation, transdermal, and connected drug delivery systems. By navigating the complex regulatory landscape of the pharmaceutical industry, the Chief Legal Officer ensures that all commercial manufacturing processes adhere to global standards. This role involves providing counsel on corporate governance and mitigating risks associated with international operations. Mike Cowhig directs the legal team to support contract negotiations with pharmaceutical partners, ensuring that agreements reflect the value of the company unique service offerings. Through proactive management of legal challenges, the Chief Legal Officer safeguards the company reputation and operational continuity. Cowhig maintains a focus on compliance, ensuring that every product development program meets the rigorous legal requirements necessary for market entry and long-term success in the global pharmaceutical sector.